Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Diabetes: later-stage trial registry
86 of 342 indexed Diabetes trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #19 of 28,707 conditions by registered trial count.
342 US clinical trials · 86 currently recruiting · #19 of 28,707 conditions by registered trial count
Diabetes: 342 US clinical trials tracked, 86 recruiting.
Diabetes is the subject of 342 registered US clinical trials on ClinicalTrials.gov, 86 of them currently open to new participants. 55 are in Phase 3-4 (later-stage) and 36 in Phase 1-2 (earlier-stage). The most active sponsor is Novo Nordisk A/S, running 41 of these trials.
Enrollment posture brief
Registry condition diabetes
OPEN 86 | RECR 25% | LATE 55 | EARLY 36 | RANK #19 | SPON 41
Volume-matched condition peers
Nearest open-share peer: Low Back Pain (25% recruiting · 123 trials)
Diabetes lists 86 open slots (25% of 342 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Diabetes on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Diabetes is recruiting below its size-band peers.
86 of 342 indexed trials (25.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Diabetes trials is spread across many organizations.
Novo Nordisk A/S accounts for 41 of 342 trials (12%). 161 distinct sponsors appear on at least one study for this condition label.
-
Typical Diabetes enrolment sits around 150 participants.
Median target enrolment is 150 among the 339 trials that report a genuine target (sentinel values excluded). 144 of those (42.5%) plan for fewer than 100 participants.
-
Diabetes research is mostly interventional.
263 interventional and 79 observational studies make up this index (76.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
342 total, page 6 of 7
Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy
Endo Pharmaceuticals
NCT00903851
Insulin Dosing Practices in Persons With Diabetes on Multiple Daily Injections
Joslin Diabetes Center
NCT02914730
Way to Health, Healthy Measures
University of Pennsylvania
NCT01282957
Evaluation of Labeling Comprehension and Performance of a New Blood Glucose Meter System
Ascensia Diabetes Care
NCT00804596
The Impact of Low-fat and Full-fat Dairy Consumption on Glucose Homeostasis (DAIRY Study)
Fred Hutchinson Cancer Center
NCT02663544
Improving Neuropathy and Mobility in People With Early Diabetes
VA Office of Research and Development
NCT00780559
Evaluation of a Lifestyle Medicine Practice
Ohio University
NCT03739034
A Study of the Treatment of Type 2 Diabetes With an Insulin Infusion Pump
Novo Nordisk A/S
NCT00115973
Improving Diabetes After Bariatric Surgery
University of Pittsburgh
NCT00676923
The Effect of NN1250 in Subjects With Type 2 Diabetes of Different Race and/or Ethnic Origin
Novo Nordisk A/S
NCT01043510
BVA-200 vs BVA-100 Validation Study
Daxor Corporation
NCT06227819
Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Healthy Volunteers
Novo Nordisk A/S
NCT01489644
Effect of Renal Impairment on the Pharmacokinetics of NN9535
Novo Nordisk A/S
NCT00833716
Comparison of Glycemic Control Achieved With 2 Different Needles
Novo Nordisk A/S
NCT00572052
Fast Food Study: Assessment of the Effects of Fast-Food on Inflammatory Markers
National Institute on Aging (NIA)
NCT00233311
Monitoring the Infusion Pressure in Insulin Infusion Sets in Healthy Adults
Becton, Dickinson and Company
NCT02382536
The Triglyceride Lowering Effect of an Omega-3 Fat (DHA) in Addition to Statin Therapy for Patients With CAD or Diabetes
Maine Center for Lipids and Cardiovascular Health
NCT00360217
Evaluation of Group Lifestyle Balance Maintenance Strategies
University of Pittsburgh
NCT00869609
Effectiveness of Adding Subcutaneous Long-acting Glargine to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy
University of Colorado, Denver
NCT01153100
Soybean Oil Trial of cArdiovascular Risk
USDA Beltsville Human Nutrition Research Center
NCT02404207
Biomarker Guided Therapies in Stage A/B Heart Failure
VA Office of Research and Development
NCT02230891
Hypoglycemia in Hospitalized Patients
University of Pittsburgh
NCT02228642
Effect of Resvida, a Comparison With Calorie Restriction Regimen
Washington University School of Medicine
NCT00823381
Nonvisual Foot Examination for People With Diabetes and Visual Impairment
Case Western Reserve University
NCT02102958
The Effects of Anti-Inflammatory Treatment on Insulin Resistance in Healthy Volunteers
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00339833
Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00862433
Addressing Diabetes Together
Mayo Clinic
NCT03046498
Vitamin D for Improving Metabolic Control and Depressive Symptoms
Loyola University
NCT01185574
Diet Composition and Cardiometabolic Risk Reduction in Adults With SCI
University of Alabama at Birmingham
NCT02630524
Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism
Nathan Kline Institute for Psychiatric Research
NCT00287820
Community Servings: Food as Medicine for Diabetes
Massachusetts General Hospital
NCT02426138
Distal Peripheral Neuropathy in Type 2 Diabetes
New York University
NCT05104047
Gene Expression Variation and Implant Wound Healing Among Smokers and Diabetics
University of North Carolina, Chapel Hill
NCT01663298
Comparison of SoloSTAR With a Syringe-administered Glargine Insulin in Diabetic Patients From the Hospital
University of Colorado, Denver
NCT01203774
Metabolic Parameters 3 Months, 9 Months, and 2 Years After Bariatric Surgery
The University of Texas Health Science Center, Houston
NCT00178633
De Novo Lipogenesis, Lipid and Carbohydrate Metabolism in Non-alcoholic Fatty Liver Disease
University of California, San Francisco
NCT00714129
Developing an Adaptive Lifestyle Intervention Program in Family Medicine Clinics
University of Alabama at Birmingham
NCT04392284
IMPACT: Inactivity Monitoring and Physical Activity Controlled Trial
The University of Texas Medical Branch, Galveston
NCT01869348
A Phase 1, Study to Evaluate HTI-2088 Tablet
Hengrui Therapeutics
NCT03203811
Peer-delivered and Technology-Assisted Integrated Illness Management and Recovery
Dartmouth-Hitchcock Medical Center
NCT04481737
STEP AND GO: A Study of Technology-based Exercise Promotion
The University of Texas Medical Branch, Galveston
NCT01953224
Change of Fructose to Fat in South Asians
The Rogosin Institute
NCT01562782
The Effect of Tight Glycemic Control on Surgical Site Infection Rates in Patients Undergoing Open Heart Surgery
James A. Haley Veterans Administration Hospital
NCT01831154
A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes
Novo Nordisk A/S
NCT01999322
TEAMcare for Diabetes in Mental Health Centers
University of Washington
NCT02011529
Tailored Home-Based Exercise Program for Multiple Chronic Conditions
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03874754
Study to Assess PK, Safety and Tolerability in Patients With DM and CKD
DiaMedica Therapeutics
NCT03795389
A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose
Carmot Therapeutics
NCT04973111
Risk Factors for Implant Bone Loss in Patients With Diabetes Mellitus
University of Michigan
NCT00933491
Navigator II Continuous Glucose Monitor Home Use Study
Abbott Diabetes Care
NCT01455064
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 23 |
| Phase 2 | 13 |
| Phase 3 | 37 |
| Phase 4 | 18 |
Top Sponsors
Named interventions
Most-linked intervention names on Diabetes records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Diabetes trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Diabetes page
342 registered trials, 86 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 86 Diabetes trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Novo Nordisk A/S sponsors the most Diabetes trials on record, review their full trial history before evaluating a specific study. See Novo Nordisk A/S's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diabetes condition card totals 342 registered trials; most-linked intervention insulin degludec; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.